Another data face-off between the two anti-CD38 multiple myeloma drugs—Johnson & Johnson’s Darzalex and Sanofi’s Sarclisa—took place at the 65th American Society of Hematology meeting. Both regimens showed strong efficacy data in newly diagnosed patients, but only one result is considered practice-changing right now.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,